news
Novel CAR T-cell immunotherapy eradicates solid tumours in mice
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
List view / Grid view
Chimeric Antigen Receptors (CARs)
article
TCR therapy – an attractive alternative to CAR T
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
news
Using blue light to control CAR T cells and destroy tumours
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
news
Precise features of CAR T cell-resistant cancer have been identified
The mechanism that prevents destruction of cancer cells by CAR T-cell therapy has been identified by researchers in Pennsylvania.
whitepaper
Application note: CAR T Cell Research
Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.
article
Using droplet digital PCR to monitor the safety of CAR T cells
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
news
New generation of CAR T cells developed
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.
article
Expert view: Opportunities in flow cytometry
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
news
HER2-targeted CAR T-cell therapy shows promise in patients with sarcoma
A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in paediatric and adult patients with advanced HER2-positive sarcoma...
news
Heating up tumours could make CAR T therapy more effective
When a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumour growth for up to 20 days in mice...
news
Explore next generation therapeutics and ATMPS in May
The 13th annual World Advanced Therapies & Regenerative Medicine Congress brings together 1000+ attendees and explores the rapidly developing world of next generation therapeutics and ATMPS.
news
Dual target CAR T cell therapy could target a range of tumours
21 June 2016 | By Victoria White, Digital Content Producer
A Penn Medicine preclinical study shows how an antibody - carbohydrate combination CAR T cell therapy could apply to range of cancer types...
